These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Epstein - Barr virus positive T and NK-cell lymphoproliferations: Morphological features and differential diagnosis. Montes-Mojarro IA; Kim WY; Fend F; Quintanilla-Martinez L Semin Diagn Pathol; 2020 Jan; 37(1):32-46. PubMed ID: 31889602 [TBL] [Abstract][Full Text] [Related]
30. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Zhang Y; Nagata H; Ikeuchi T; Mukai H; Oyoshi MK; Demachi A; Morio T; Wakiguchi H; Kimura N; Shimizu N; Yamamoto K Br J Haematol; 2003 Jun; 121(5):805-14. PubMed ID: 12780797 [TBL] [Abstract][Full Text] [Related]
31. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Remer M; Al-Shamkhani A; Glennie M; Johnson P Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334 [TBL] [Abstract][Full Text] [Related]
32. [Clinicopathologic features of systemic EBV-positive T/NK-cell lymphoproliferative disease in adults]. Zheng XD; Zhou XG; Jin Y; Xie JL; Wei XJ; Chen SY; Mei X; Gong LP; Lü BB Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):227-34. PubMed ID: 21615995 [TBL] [Abstract][Full Text] [Related]
33. Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders. Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Ogata M; Daa T; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M BMC Cancer; 2022 Dec; 22(1):1342. PubMed ID: 36544095 [TBL] [Abstract][Full Text] [Related]
34. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Iwatsuki K; Satoh M; Yamamoto T; Oono T; Morizane S; Ohtsuka M; Xu ZG; Suzuki D; Tsuji K Arch Dermatol; 2006 May; 142(5):587-95. PubMed ID: 16702496 [TBL] [Abstract][Full Text] [Related]
35. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073 [TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884 [TBL] [Abstract][Full Text] [Related]
37. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Tse E; Kwong YL Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733 [TBL] [Abstract][Full Text] [Related]
38. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Loomis R; Carbone R; Reiss M; Lacy J Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752 [TBL] [Abstract][Full Text] [Related]
39. Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody. Sugata K; Yasunaga J; Miura M; Akari H; Utsunomiya A; Nosaka K; Watanabe Y; Suzushima H; Koh KR; Nakagawa M; Kohara M; Matsuoka M Sci Rep; 2016 Jun; 6():27150. PubMed ID: 27250643 [TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. Cohen JI; Iwatsuki K; Ko YH; Kimura H; Manoli I; Ohshima K; Pittaluga S; Quintanilla-Martinez L; Jaffe ES Leuk Lymphoma; 2020 Apr; 61(4):808-819. PubMed ID: 31833428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]